trpv6  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Alomone Labs trpv6
    Spatial expression of uterine (A) and placental (B) <t>TRPV6</t> expression in a time-dependent manner . A, Rat uteri from P5.5 to P10.5 were separately shown into the non-attached or attached uteri using anit-TRPV6 serum. u, attached uterus; f, placenta-like structure; arrows, epithelial and glandular cells. B, Rat placentas from P11.5 to P13.5 were presented in a time-dependent manner. la, labyrinth zone; sp, spongy zone; gc, giant cells; arrows, fetal membrane.
    Trpv6, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trpv6/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    trpv6 - by Bioz Stars, 2021-12
    94/100 stars

    Images

    1) Product Images from "Uterine and placental expression of TRPV6 gene is regulated via progesterone receptor- or estrogen receptor-mediated pathways during pregnancy in rodents"

    Article Title: Uterine and placental expression of TRPV6 gene is regulated via progesterone receptor- or estrogen receptor-mediated pathways during pregnancy in rodents

    Journal: Reproductive Biology and Endocrinology : RB & E

    doi: 10.1186/1477-7827-7-49

    Spatial expression of uterine (A) and placental (B) TRPV6 expression in a time-dependent manner . A, Rat uteri from P5.5 to P10.5 were separately shown into the non-attached or attached uteri using anit-TRPV6 serum. u, attached uterus; f, placenta-like structure; arrows, epithelial and glandular cells. B, Rat placentas from P11.5 to P13.5 were presented in a time-dependent manner. la, labyrinth zone; sp, spongy zone; gc, giant cells; arrows, fetal membrane.
    Figure Legend Snippet: Spatial expression of uterine (A) and placental (B) TRPV6 expression in a time-dependent manner . A, Rat uteri from P5.5 to P10.5 were separately shown into the non-attached or attached uteri using anit-TRPV6 serum. u, attached uterus; f, placenta-like structure; arrows, epithelial and glandular cells. B, Rat placentas from P11.5 to P13.5 were presented in a time-dependent manner. la, labyrinth zone; sp, spongy zone; gc, giant cells; arrows, fetal membrane.

    Techniques Used: Expressing

    Placental TRPV6 mRNA expression during pregnancy in rats . Placentas were collected daily from P13.5 to P21.5. Placenta TRPV6 mRNA was examined by RT-PCR (Top panel, agarose gel image) and Real-Time PCR (Bottom panel, line graph). The line graph represents the analysis of Real-Time PCR data expressed as a percentage of TRPV6/HPRT1 (mean ± SEM of duplicates).
    Figure Legend Snippet: Placental TRPV6 mRNA expression during pregnancy in rats . Placentas were collected daily from P13.5 to P21.5. Placenta TRPV6 mRNA was examined by RT-PCR (Top panel, agarose gel image) and Real-Time PCR (Bottom panel, line graph). The line graph represents the analysis of Real-Time PCR data expressed as a percentage of TRPV6/HPRT1 (mean ± SEM of duplicates).

    Techniques Used: Expressing, Reverse Transcription Polymerase Chain Reaction, Agarose Gel Electrophoresis, Real-time Polymerase Chain Reaction

    Localization of uterine TRPV6 at P6.5 . Left panel, low power image of uterus showing representative TRPV6 immuno-positive regions restricted to three histological areas (A – C) as spotted rectangles. A, glandular epithelium; B, putative implantation site; C, epithelial layer. 'No first antibody' indicates immunoreactivity without anti-TRPV6 treatment, as a negative control. Arrows indicate immuno-positive staining.
    Figure Legend Snippet: Localization of uterine TRPV6 at P6.5 . Left panel, low power image of uterus showing representative TRPV6 immuno-positive regions restricted to three histological areas (A – C) as spotted rectangles. A, glandular epithelium; B, putative implantation site; C, epithelial layer. 'No first antibody' indicates immunoreactivity without anti-TRPV6 treatment, as a negative control. Arrows indicate immuno-positive staining.

    Techniques Used: Negative Control, Staining

    Localization of placental TRPV6 at P20.5 . Left panel, overview of placenta divided into three distinct areas (A to C) showing TRPV6 immuno-staining as spotted rectangles. A, inner labyrinth area; B, middle labyrinth; C, spongy zone. 'No first antibody' indicates immunoreactivity without anti-TRPV6 treatment, as a negative control. Arrows indicate immuno-positive staining.
    Figure Legend Snippet: Localization of placental TRPV6 at P20.5 . Left panel, overview of placenta divided into three distinct areas (A to C) showing TRPV6 immuno-staining as spotted rectangles. A, inner labyrinth area; B, middle labyrinth; C, spongy zone. 'No first antibody' indicates immunoreactivity without anti-TRPV6 treatment, as a negative control. Arrows indicate immuno-positive staining.

    Techniques Used: Immunostaining, Negative Control, Staining

    Effects of steroid receptor antagonists on uterine and placental TRPV6 mRNA expressions . Panel A (uteri at P5.5) and B (placenta at P20.5) presented the rat TRPV6 mRNA levels. Four groups of pregnant rats (n = 4 per group) were treated with ethanol as a negative control (VE), progesterone receptor antagonist (RU, 2.5 mg per rat), or estrogen receptor antagonist (ICI, 0.5 mg per mouse). Panel C (uteri at P10.5) and D (placenta at P10.5) showed the mouse TRPV6 mRNA expressions. Four groups of pregnant mice (n = 4 per group) were treated with ethanol as a negative control (VE), progesterone receptor antagonist (RU, 25 μg per mouse) or estrogen receptor antagonist (ICI, 2 μg per mouse). Murine TRPV6 mRNA levels were examined by real-time PCR. The bar graph represents the analysis of real-time PCR data expressed as a percentage of TRPV6/HPRT1 (mean ± SEM of duplicates). a, statistically significant compared to a vehicle ( P
    Figure Legend Snippet: Effects of steroid receptor antagonists on uterine and placental TRPV6 mRNA expressions . Panel A (uteri at P5.5) and B (placenta at P20.5) presented the rat TRPV6 mRNA levels. Four groups of pregnant rats (n = 4 per group) were treated with ethanol as a negative control (VE), progesterone receptor antagonist (RU, 2.5 mg per rat), or estrogen receptor antagonist (ICI, 0.5 mg per mouse). Panel C (uteri at P10.5) and D (placenta at P10.5) showed the mouse TRPV6 mRNA expressions. Four groups of pregnant mice (n = 4 per group) were treated with ethanol as a negative control (VE), progesterone receptor antagonist (RU, 25 μg per mouse) or estrogen receptor antagonist (ICI, 2 μg per mouse). Murine TRPV6 mRNA levels were examined by real-time PCR. The bar graph represents the analysis of real-time PCR data expressed as a percentage of TRPV6/HPRT1 (mean ± SEM of duplicates). a, statistically significant compared to a vehicle ( P

    Techniques Used: Negative Control, Mouse Assay, Real-time Polymerase Chain Reaction

    Expression of uterine TRPV6 mRNA during pregnancy in rats . Uteri of gestating rats (n = 2) were collected daily from P0.5 to P21.5, and expression of TRPV6 mRNA was assayed by RT-PCR (Top panel, agarose gel image) and Real-Time PCR (Bottom panel, line graph). The unattached uteri containing uterine epithelial cells were used as a RNA preparation from P1.3.5. The line graph shows the analysis of Real-Time PCR data expressed as a percentage of TRPV6/HPRT1 (mean ± SEM of duplicates).
    Figure Legend Snippet: Expression of uterine TRPV6 mRNA during pregnancy in rats . Uteri of gestating rats (n = 2) were collected daily from P0.5 to P21.5, and expression of TRPV6 mRNA was assayed by RT-PCR (Top panel, agarose gel image) and Real-Time PCR (Bottom panel, line graph). The unattached uteri containing uterine epithelial cells were used as a RNA preparation from P1.3.5. The line graph shows the analysis of Real-Time PCR data expressed as a percentage of TRPV6/HPRT1 (mean ± SEM of duplicates).

    Techniques Used: Expressing, Reverse Transcription Polymerase Chain Reaction, Agarose Gel Electrophoresis, Real-time Polymerase Chain Reaction

    2) Product Images from "Effects of Bisphenol A and 4-tert-Octylphenol on Embryo Implantation Failure in Mouse"

    Article Title: Effects of Bisphenol A and 4-tert-Octylphenol on Embryo Implantation Failure in Mouse

    Journal: International Journal of Environmental Research and Public Health

    doi: 10.3390/ijerph15081614

    E2, BPA, and OP change the expressions of TRPV6 , TRPV5 , PMCA1 , and NCX1 in maternal uterus and implantation sites. Mice were sacrificed at GD 4.5 (24 h after final injection) to collect uterus tissues and at GD 5.5 (after 48 h after final injection) to collect implantation sites. The mRNA expressions of calcium transporter channel genes in uterus and implantation sites were assessed. The mRNA levels of TRPV6 , TRPV5 , PMCA1 , and NCX1 genes were measured by using real-time PCR and were normalized to that of 18S ribosomal RNA (RN18S). In uterus, ( a ) the expressions of TRPV5 mRNA were significantly high in the E2, E2 + ICI, BPA + ICI, OP, and OP + ICI groups; ( b ) TRPV6 mRNA level changes were similar to those for TRPV5 expression. mRNA expression of TRPV5 and TRPV6 in uteri were higher in BPA + ICI group than in the BPA group; ( c , d ) mRNA level of PMCA1 and NCX1 were significantly decreased by E2 and E2 + ICI. In implantation sites; ( e – h ) the mRNA levels of TRPV6 , TRPV5 , PMCA1 , and NCX1 , respectively, were markedly low in all groups. Statistical significance was determined by two-way ANOVA. * p
    Figure Legend Snippet: E2, BPA, and OP change the expressions of TRPV6 , TRPV5 , PMCA1 , and NCX1 in maternal uterus and implantation sites. Mice were sacrificed at GD 4.5 (24 h after final injection) to collect uterus tissues and at GD 5.5 (after 48 h after final injection) to collect implantation sites. The mRNA expressions of calcium transporter channel genes in uterus and implantation sites were assessed. The mRNA levels of TRPV6 , TRPV5 , PMCA1 , and NCX1 genes were measured by using real-time PCR and were normalized to that of 18S ribosomal RNA (RN18S). In uterus, ( a ) the expressions of TRPV5 mRNA were significantly high in the E2, E2 + ICI, BPA + ICI, OP, and OP + ICI groups; ( b ) TRPV6 mRNA level changes were similar to those for TRPV5 expression. mRNA expression of TRPV5 and TRPV6 in uteri were higher in BPA + ICI group than in the BPA group; ( c , d ) mRNA level of PMCA1 and NCX1 were significantly decreased by E2 and E2 + ICI. In implantation sites; ( e – h ) the mRNA levels of TRPV6 , TRPV5 , PMCA1 , and NCX1 , respectively, were markedly low in all groups. Statistical significance was determined by two-way ANOVA. * p

    Techniques Used: Mouse Assay, Injection, Real-time Polymerase Chain Reaction, Expressing

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Alomone Labs trpv6 antibody
    Localisation of <t>TRPV6</t> protein in the placentomes and fetal membranes in cows with (RFM) (C, D) and without retained fetal membranes (DFM) (A, B). Strongest labeling of TRPV6 protein was seen in the fetal membranes (FM) of all animals and in the maternal crypt epithelium (ME) of cows with RFM (D).
    Trpv6 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trpv6 antibody/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    trpv6 antibody - by Bioz Stars, 2021-12
    94/100 stars
      Buy from Supplier

    86
    Alomone Labs trpv6
    E2, BPA, and OP change the expressions of <t>TRPV6</t> , TRPV5 , PMCA1 , and NCX1 in maternal uterus and implantation sites. Mice were sacrificed at GD 4.5 (24 h after final injection) to collect uterus tissues and at GD 5.5 (after 48 h after final injection) to collect implantation sites. The mRNA expressions of calcium transporter channel genes in uterus and implantation sites were assessed. The mRNA levels of TRPV6 , TRPV5 , PMCA1 , and NCX1 genes were measured by using real-time PCR and were normalized to that of 18S ribosomal RNA (RN18S). In uterus, ( a ) the expressions of TRPV5 mRNA were significantly high in the E2, E2 + ICI, BPA + ICI, OP, and OP + ICI groups; ( b ) TRPV6 mRNA level changes were similar to those for TRPV5 expression. mRNA expression of TRPV5 and TRPV6 in uteri were higher in BPA + ICI group than in the BPA group; ( c , d ) mRNA level of PMCA1 and NCX1 were significantly decreased by E2 and E2 + ICI. In implantation sites; ( e – h ) the mRNA levels of TRPV6 , TRPV5 , PMCA1 , and NCX1 , respectively, were markedly low in all groups. Statistical significance was determined by two-way ANOVA. * p
    Trpv6, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trpv6/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    trpv6 - by Bioz Stars, 2021-12
    86/100 stars
      Buy from Supplier

    Image Search Results


    Localisation of TRPV6 protein in the placentomes and fetal membranes in cows with (RFM) (C, D) and without retained fetal membranes (DFM) (A, B). Strongest labeling of TRPV6 protein was seen in the fetal membranes (FM) of all animals and in the maternal crypt epithelium (ME) of cows with RFM (D).

    Journal: Reproductive Biology and Endocrinology : RB & E

    Article Title: TRPV6 and Calbindin-D9k-expression and localization in the bovine uterus and placenta during pregnancy

    doi: 10.1186/1477-7827-10-66

    Figure Lengend Snippet: Localisation of TRPV6 protein in the placentomes and fetal membranes in cows with (RFM) (C, D) and without retained fetal membranes (DFM) (A, B). Strongest labeling of TRPV6 protein was seen in the fetal membranes (FM) of all animals and in the maternal crypt epithelium (ME) of cows with RFM (D).

    Article Snippet: As a negative control for the TRPV6 antibody, samples were preincubated with a specific control antigen (Alomone labs, Israel).

    Techniques: Labeling

    Uterine and placentomal TRPV6 and CaBP-9k mRNA expression. TRPV6 and CaBP-9k mRNA expression in the intercaruncular wall (Figure 1A, C) and in the placenta (n ≥ 3 animals/month) (Figure 1B, D) from the 2 nd to 9 th months of pregnancy, determined by real-time PCR. Bars with ** differ significantly (p

    Journal: Reproductive Biology and Endocrinology : RB & E

    Article Title: TRPV6 and Calbindin-D9k-expression and localization in the bovine uterus and placenta during pregnancy

    doi: 10.1186/1477-7827-10-66

    Figure Lengend Snippet: Uterine and placentomal TRPV6 and CaBP-9k mRNA expression. TRPV6 and CaBP-9k mRNA expression in the intercaruncular wall (Figure 1A, C) and in the placenta (n ≥ 3 animals/month) (Figure 1B, D) from the 2 nd to 9 th months of pregnancy, determined by real-time PCR. Bars with ** differ significantly (p

    Article Snippet: As a negative control for the TRPV6 antibody, samples were preincubated with a specific control antigen (Alomone labs, Israel).

    Techniques: Expressing, Real-time Polymerase Chain Reaction

    Western blot analyses of placental TRPV6 and CaBP-9k postpartum in cows with (RFM) and without retained fetal membranes (DFM). A) Representative Western blot of TRPV6 in the placenta. Bands of approximately 75 kDa were detected in all animals. B) Relative expression of TRPV6 was determined by measuring the optical density relative to GAPDH using ImageJ software. Significant changes in expression levels were not detected (p > 0.05). C) Representative Western blot of CaBP-9k. D) The relative expression levels to GAPDH were determined by densitometry using ImageJ software. No significant changes were detected (p > 0.05). Data were analyzed by an unpaired one-tailed t-test and are presented as means ± SD.

    Journal: Reproductive Biology and Endocrinology : RB & E

    Article Title: TRPV6 and Calbindin-D9k-expression and localization in the bovine uterus and placenta during pregnancy

    doi: 10.1186/1477-7827-10-66

    Figure Lengend Snippet: Western blot analyses of placental TRPV6 and CaBP-9k postpartum in cows with (RFM) and without retained fetal membranes (DFM). A) Representative Western blot of TRPV6 in the placenta. Bands of approximately 75 kDa were detected in all animals. B) Relative expression of TRPV6 was determined by measuring the optical density relative to GAPDH using ImageJ software. Significant changes in expression levels were not detected (p > 0.05). C) Representative Western blot of CaBP-9k. D) The relative expression levels to GAPDH were determined by densitometry using ImageJ software. No significant changes were detected (p > 0.05). Data were analyzed by an unpaired one-tailed t-test and are presented as means ± SD.

    Article Snippet: As a negative control for the TRPV6 antibody, samples were preincubated with a specific control antigen (Alomone labs, Israel).

    Techniques: Western Blot, Expressing, Software, One-tailed Test

    Immunolabelling of CaBP-9k in placentomes and adherent fetal membranes. Localisation of CaBP-9k during pregnancy with strong signals in the inner layer (IL) of the place tome and in the fetal membranes (FM) compared to the outer labyrinth layer (OL) (A, C). Strong staining in the binucleate trophoblast cells (BNC) and in the maternal epithelium (ME) inside the place tome (B, C). Figure 2 F shows a negative control, without anti-TRPV6 treatment. Scale bars indicate 200 μm.

    Journal: Reproductive Biology and Endocrinology : RB & E

    Article Title: TRPV6 and Calbindin-D9k-expression and localization in the bovine uterus and placenta during pregnancy

    doi: 10.1186/1477-7827-10-66

    Figure Lengend Snippet: Immunolabelling of CaBP-9k in placentomes and adherent fetal membranes. Localisation of CaBP-9k during pregnancy with strong signals in the inner layer (IL) of the place tome and in the fetal membranes (FM) compared to the outer labyrinth layer (OL) (A, C). Strong staining in the binucleate trophoblast cells (BNC) and in the maternal epithelium (ME) inside the place tome (B, C). Figure 2 F shows a negative control, without anti-TRPV6 treatment. Scale bars indicate 200 μm.

    Article Snippet: As a negative control for the TRPV6 antibody, samples were preincubated with a specific control antigen (Alomone labs, Israel).

    Techniques: Staining, Negative Control

    Immunolabelling of TRPV6 in the placentomes and adherent fetal membranes. Localisation of TRPV6 during pregnancy in the placenta and adherent membranes with strong staining in the inner layer (IL) of the place tome (A, D) and the adherent fetal membranes (FM) (A, C). Considerably weaker staining in the middle (ML) and outer labyrinth (OL) layers (A, B). Scale bars indicate 200 μm.

    Journal: Reproductive Biology and Endocrinology : RB & E

    Article Title: TRPV6 and Calbindin-D9k-expression and localization in the bovine uterus and placenta during pregnancy

    doi: 10.1186/1477-7827-10-66

    Figure Lengend Snippet: Immunolabelling of TRPV6 in the placentomes and adherent fetal membranes. Localisation of TRPV6 during pregnancy in the placenta and adherent membranes with strong staining in the inner layer (IL) of the place tome (A, D) and the adherent fetal membranes (FM) (A, C). Considerably weaker staining in the middle (ML) and outer labyrinth (OL) layers (A, B). Scale bars indicate 200 μm.

    Article Snippet: As a negative control for the TRPV6 antibody, samples were preincubated with a specific control antigen (Alomone labs, Israel).

    Techniques: Staining

    Immunolabelling of TRPV6 in the uterine endometrium. Localisation of uterine TRPV6 during pregnancy with strong labelling in the glandular (GE) and luminal epithelia (LE). Figure 2F shows a negative control, without anti-TRPV6 treatment. Scale bars indicate 200 μm.

    Journal: Reproductive Biology and Endocrinology : RB & E

    Article Title: TRPV6 and Calbindin-D9k-expression and localization in the bovine uterus and placenta during pregnancy

    doi: 10.1186/1477-7827-10-66

    Figure Lengend Snippet: Immunolabelling of TRPV6 in the uterine endometrium. Localisation of uterine TRPV6 during pregnancy with strong labelling in the glandular (GE) and luminal epithelia (LE). Figure 2F shows a negative control, without anti-TRPV6 treatment. Scale bars indicate 200 μm.

    Article Snippet: As a negative control for the TRPV6 antibody, samples were preincubated with a specific control antigen (Alomone labs, Israel).

    Techniques: Negative Control

    Placental TRPV6 and CaBP-9k mRNA expression post partum in cows with and without retained fetal membranes. Detection of TRPV6 (A) and Calbindin-D9k (CaBP-9k) (B) mRNA levels in the placenta of postpartum cows that retained the fetal membranes for more than 12 hours (RFM; n = 5) and cows that discharged the fetal membranes (DFM; n = 6), measured by real-time PCR (Taqman). No significant changes were observed (p > 0.05). Data were analyzed by an unpaired one-tailed t-test and are presented as means ± SD.

    Journal: Reproductive Biology and Endocrinology : RB & E

    Article Title: TRPV6 and Calbindin-D9k-expression and localization in the bovine uterus and placenta during pregnancy

    doi: 10.1186/1477-7827-10-66

    Figure Lengend Snippet: Placental TRPV6 and CaBP-9k mRNA expression post partum in cows with and without retained fetal membranes. Detection of TRPV6 (A) and Calbindin-D9k (CaBP-9k) (B) mRNA levels in the placenta of postpartum cows that retained the fetal membranes for more than 12 hours (RFM; n = 5) and cows that discharged the fetal membranes (DFM; n = 6), measured by real-time PCR (Taqman). No significant changes were observed (p > 0.05). Data were analyzed by an unpaired one-tailed t-test and are presented as means ± SD.

    Article Snippet: As a negative control for the TRPV6 antibody, samples were preincubated with a specific control antigen (Alomone labs, Israel).

    Techniques: Expressing, Real-time Polymerase Chain Reaction, One-tailed Test

    Western blot analyses of endometrial and placentomal TRPV6 protein during pregnancy. A) Representative Western blot of TRPV6 protein expression in the uterine wall (n = 3 animals/month). Bands of approximately 75 kDa were detected. An additional band of approximately 90 kDa was seen in the 2 nd and 3 rd months. After incubation with N-glycosidase F (PNGase F), only the smaller band of 75 kDa was seen, demonstrating that the other band is the glycosylated variant of TRPV6. As a negative control, samples were preincubated with a control antigen. B) Relative expression of TRPV6 to GAPDH was determined by densitometry using ImageJ software. No significant changes were detected (p > 0.05). C) Representative Western blot analyses of TRPV6 in the placenta from 2 nd to 9 th months of pregnancy (n = 3 animals/month). D) The expression of TRPV6 relative to GAPDH was determined by measuring the optical density using ImageJ software. No significant changes (p > 0.05) were detected. Data were analysed using a parametric one-way analysis of variance (ANOVA), followed by Dunnett’s comparison test, where the second month was taken as the control group, and are presented as means ± SD.

    Journal: Reproductive Biology and Endocrinology : RB & E

    Article Title: TRPV6 and Calbindin-D9k-expression and localization in the bovine uterus and placenta during pregnancy

    doi: 10.1186/1477-7827-10-66

    Figure Lengend Snippet: Western blot analyses of endometrial and placentomal TRPV6 protein during pregnancy. A) Representative Western blot of TRPV6 protein expression in the uterine wall (n = 3 animals/month). Bands of approximately 75 kDa were detected. An additional band of approximately 90 kDa was seen in the 2 nd and 3 rd months. After incubation with N-glycosidase F (PNGase F), only the smaller band of 75 kDa was seen, demonstrating that the other band is the glycosylated variant of TRPV6. As a negative control, samples were preincubated with a control antigen. B) Relative expression of TRPV6 to GAPDH was determined by densitometry using ImageJ software. No significant changes were detected (p > 0.05). C) Representative Western blot analyses of TRPV6 in the placenta from 2 nd to 9 th months of pregnancy (n = 3 animals/month). D) The expression of TRPV6 relative to GAPDH was determined by measuring the optical density using ImageJ software. No significant changes (p > 0.05) were detected. Data were analysed using a parametric one-way analysis of variance (ANOVA), followed by Dunnett’s comparison test, where the second month was taken as the control group, and are presented as means ± SD.

    Article Snippet: As a negative control for the TRPV6 antibody, samples were preincubated with a specific control antigen (Alomone labs, Israel).

    Techniques: Western Blot, Expressing, Incubation, Variant Assay, Negative Control, Software

    Effects of TRPV6 siRNA on the cell motility rate of LNCaP cells. Representative images (A) and graph (B) of the scratch wound-healing assays show that knockdown of TRPV6 suppressed cell motility in LNCaP cells. Cells (1×10 5 ) were seeded into 6-well plates, incubated for 48 hours, transfected with siRNA for TRPV6, and 24 hours later, a constant sized artificial gap was created with a pipette tip in the cell monolayer that was more than 90% saturated. Afterwards, the degree of movement of the cells filling the gap was compared by photographing at 0, 24, and 48 hours with a microscope (magnification ×100). Cells were treated with 1 nM or 100 nM DHT as described in the “MATERIALS AND METHODS” section. DHT, dihydrotestosterone; siTRPV6, small interfering RNA targeting transient receptor potential cation channel vanilloid subfamily number 6; CON, control scrambled siRNA. Data are presented as the mean±standard error of the mean of three independent experiments. * p

    Journal: Investigative and Clinical Urology

    Article Title: RNA interference mediated suppression of TRPV6 inhibits the progression of prostate cancer in vitro by modulating cathepsin B and MMP9 expression

    doi: 10.4111/icu.20200511

    Figure Lengend Snippet: Effects of TRPV6 siRNA on the cell motility rate of LNCaP cells. Representative images (A) and graph (B) of the scratch wound-healing assays show that knockdown of TRPV6 suppressed cell motility in LNCaP cells. Cells (1×10 5 ) were seeded into 6-well plates, incubated for 48 hours, transfected with siRNA for TRPV6, and 24 hours later, a constant sized artificial gap was created with a pipette tip in the cell monolayer that was more than 90% saturated. Afterwards, the degree of movement of the cells filling the gap was compared by photographing at 0, 24, and 48 hours with a microscope (magnification ×100). Cells were treated with 1 nM or 100 nM DHT as described in the “MATERIALS AND METHODS” section. DHT, dihydrotestosterone; siTRPV6, small interfering RNA targeting transient receptor potential cation channel vanilloid subfamily number 6; CON, control scrambled siRNA. Data are presented as the mean±standard error of the mean of three independent experiments. * p

    Article Snippet: The primary antibodies against TRPV6 used in this experiment were purchased from Alomon Labs (Jerusalem, Israel), whereas the others were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).

    Techniques: Incubation, Transfection, Transferring, Microscopy, Small Interfering RNA

    Effects of TRPV6 siRNA on the proliferation of LNCaP cells. The viability of LNCaP cells was measured by WST-1 assay at 48 hours after transfection with TRPV6 siRNA. Cells were treated with 1 nM or 100 nM DHT as described in the “MATERIALS AND METHODS” section. Cell growth is expressed relative to the value of the negative control, which was set to 100%. siTRPV6, small interfering RNA targeting transient receptor potential cation channel vanilloid subfamily number 6; CON, control scrambled siRNA; DHT, dihydrotestosterone. Data are presented as the mean±standard error of the mean of three independent experiments. # p

    Journal: Investigative and Clinical Urology

    Article Title: RNA interference mediated suppression of TRPV6 inhibits the progression of prostate cancer in vitro by modulating cathepsin B and MMP9 expression

    doi: 10.4111/icu.20200511

    Figure Lengend Snippet: Effects of TRPV6 siRNA on the proliferation of LNCaP cells. The viability of LNCaP cells was measured by WST-1 assay at 48 hours after transfection with TRPV6 siRNA. Cells were treated with 1 nM or 100 nM DHT as described in the “MATERIALS AND METHODS” section. Cell growth is expressed relative to the value of the negative control, which was set to 100%. siTRPV6, small interfering RNA targeting transient receptor potential cation channel vanilloid subfamily number 6; CON, control scrambled siRNA; DHT, dihydrotestosterone. Data are presented as the mean±standard error of the mean of three independent experiments. # p

    Article Snippet: The primary antibodies against TRPV6 used in this experiment were purchased from Alomon Labs (Jerusalem, Israel), whereas the others were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).

    Techniques: WST-1 Assay, Transfection, Negative Control, Small Interfering RNA

    Knockdown efficiency of siTRPV6 in LNCaP cells. (A) The efficacies of three different kinds of small interfering RNA against TRPV6 (siTRPV6#1, siTRPV6#2, and siTRPV6#3) were analyzed by RT-PCR in LNCaP cells. siTRPV6#2 was selected for the following experiments because it blocked more TRPV6 compared with the other variants. The expression of TRPV6 is normalized to β-actin gene expression. (B) The degrees of inhibition of TRPV6 protein levels were analyzed by western blot in siTRPV6#2 transfected LNCaP cells treated with 1 nM or 100 nM DHT. The expression of TRPV6 is normalized to β-actin expression. siTRPV6, small interfering RNA targeting transient receptor potential cation channel vanilloid subfamily number 6; Blank, mock; CON, control scrambled siRNA; DHT, dihydrotestosterone. The data are presented as the mean±standard error of the mean of three independent experiments. * p

    Journal: Investigative and Clinical Urology

    Article Title: RNA interference mediated suppression of TRPV6 inhibits the progression of prostate cancer in vitro by modulating cathepsin B and MMP9 expression

    doi: 10.4111/icu.20200511

    Figure Lengend Snippet: Knockdown efficiency of siTRPV6 in LNCaP cells. (A) The efficacies of three different kinds of small interfering RNA against TRPV6 (siTRPV6#1, siTRPV6#2, and siTRPV6#3) were analyzed by RT-PCR in LNCaP cells. siTRPV6#2 was selected for the following experiments because it blocked more TRPV6 compared with the other variants. The expression of TRPV6 is normalized to β-actin gene expression. (B) The degrees of inhibition of TRPV6 protein levels were analyzed by western blot in siTRPV6#2 transfected LNCaP cells treated with 1 nM or 100 nM DHT. The expression of TRPV6 is normalized to β-actin expression. siTRPV6, small interfering RNA targeting transient receptor potential cation channel vanilloid subfamily number 6; Blank, mock; CON, control scrambled siRNA; DHT, dihydrotestosterone. The data are presented as the mean±standard error of the mean of three independent experiments. * p

    Article Snippet: The primary antibodies against TRPV6 used in this experiment were purchased from Alomon Labs (Jerusalem, Israel), whereas the others were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).

    Techniques: Small Interfering RNA, Reverse Transcription Polymerase Chain Reaction, Expressing, Inhibition, Western Blot, Transfection

    Effect of TRPV6 siRNA on the migratory capability of LNCaP cells. Representative images (A) and graph (B) of the Transwell migration assay of LNCaP cells with TRPV6 siRNA, showing suppressed migration, compared with the scrambled siRNA control. Cells were treated with 1 nM DHT as described in the “MATERIALS AND METHODS” section. siTRPV6, small interfering RNA targeting transient receptor potential cation channel vanilloid subfamily number 6; CON, control scrambled siRNA. Data are presented as the mean±standard error of the mean of three independent experiments. * p

    Journal: Investigative and Clinical Urology

    Article Title: RNA interference mediated suppression of TRPV6 inhibits the progression of prostate cancer in vitro by modulating cathepsin B and MMP9 expression

    doi: 10.4111/icu.20200511

    Figure Lengend Snippet: Effect of TRPV6 siRNA on the migratory capability of LNCaP cells. Representative images (A) and graph (B) of the Transwell migration assay of LNCaP cells with TRPV6 siRNA, showing suppressed migration, compared with the scrambled siRNA control. Cells were treated with 1 nM DHT as described in the “MATERIALS AND METHODS” section. siTRPV6, small interfering RNA targeting transient receptor potential cation channel vanilloid subfamily number 6; CON, control scrambled siRNA. Data are presented as the mean±standard error of the mean of three independent experiments. * p

    Article Snippet: The primary antibodies against TRPV6 used in this experiment were purchased from Alomon Labs (Jerusalem, Israel), whereas the others were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).

    Techniques: Transwell Migration Assay, Migration, Small Interfering RNA

    Effect of TRPV6 siRNA on the invasive capability of LNCaP cells. Representative images (A) and graph (B) of the Transwell invasion of LNCaP cells with TRPV6 inhibition and respective scrambled siRNA control. (C) Effect of TRPV6 siRNA on the protein expression of cathepsin B matrix metalloproteinase 9 (MMP9) in LNCaP cells. Both cathepsin B and MMP9 expression were reduced by TRPV6 siRNA transfection in LNCaP cells. siTRPV6, small interfering RNA targeting transient receptor potential cation channel vanilloid subfamily number 6; Blank, mock; CON, control scrambled siRNA. Data are presented as the mean±standard error of the mean of three independent experiments. # p

    Journal: Investigative and Clinical Urology

    Article Title: RNA interference mediated suppression of TRPV6 inhibits the progression of prostate cancer in vitro by modulating cathepsin B and MMP9 expression

    doi: 10.4111/icu.20200511

    Figure Lengend Snippet: Effect of TRPV6 siRNA on the invasive capability of LNCaP cells. Representative images (A) and graph (B) of the Transwell invasion of LNCaP cells with TRPV6 inhibition and respective scrambled siRNA control. (C) Effect of TRPV6 siRNA on the protein expression of cathepsin B matrix metalloproteinase 9 (MMP9) in LNCaP cells. Both cathepsin B and MMP9 expression were reduced by TRPV6 siRNA transfection in LNCaP cells. siTRPV6, small interfering RNA targeting transient receptor potential cation channel vanilloid subfamily number 6; Blank, mock; CON, control scrambled siRNA. Data are presented as the mean±standard error of the mean of three independent experiments. # p

    Article Snippet: The primary antibodies against TRPV6 used in this experiment were purchased from Alomon Labs (Jerusalem, Israel), whereas the others were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).

    Techniques: Inhibition, Expressing, Transfection, Small Interfering RNA

    Two cohorts both showed that TRPV6 played a contradicting role in predicting survival of male and female patients. Downregulation of TRPV6 was associated with a poor 3-year disease specific survival in patients with male in mRNA ( a ) and protein cohort ( c ). Downregulation of TRPV6 was significantly associated with favorable 3-year disease specific survival in patients with female in mRNA ( b ) and protein cohort ( d )

    Journal: Diagnostic Pathology

    Article Title: TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma

    doi: 10.1186/s13000-016-0457-7

    Figure Lengend Snippet: Two cohorts both showed that TRPV6 played a contradicting role in predicting survival of male and female patients. Downregulation of TRPV6 was associated with a poor 3-year disease specific survival in patients with male in mRNA ( a ) and protein cohort ( c ). Downregulation of TRPV6 was significantly associated with favorable 3-year disease specific survival in patients with female in mRNA ( b ) and protein cohort ( d )

    Article Snippet: The slides were then incubated with rabbit polyclonal antibody against TRPV6 (alomone labs) at a dilution of 1:50 at 4 °C overnight and subsequently incubated with biotinylated goat anti-rabbit immunoglobulin at a concentration of 1:100 for 30 min at 37 °C.

    Techniques:

    TRPV6 was down-regulated in esophageal squamous cell carcinoma. TRPV6 mRNA was markedly decreased in tumor tissues than that in paired adjacent non-tumor tissues ( a and b ). TRPV6 mRNA was down-regulated in ten esophageal squamous cell carcinoma cell lines when compared with pooled samples from 45 patients of adjacent non-tumor tissues (Np) ( c )

    Journal: Diagnostic Pathology

    Article Title: TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma

    doi: 10.1186/s13000-016-0457-7

    Figure Lengend Snippet: TRPV6 was down-regulated in esophageal squamous cell carcinoma. TRPV6 mRNA was markedly decreased in tumor tissues than that in paired adjacent non-tumor tissues ( a and b ). TRPV6 mRNA was down-regulated in ten esophageal squamous cell carcinoma cell lines when compared with pooled samples from 45 patients of adjacent non-tumor tissues (Np) ( c )

    Article Snippet: The slides were then incubated with rabbit polyclonal antibody against TRPV6 (alomone labs) at a dilution of 1:50 at 4 °C overnight and subsequently incubated with biotinylated goat anti-rabbit immunoglobulin at a concentration of 1:100 for 30 min at 37 °C.

    Techniques:

    Representative of TRPV6 expression in three pairs of ESCC tumor and adjacent non-tumor tissue detected by immunostaining with anti-TRPV6 antibody ( brown ). (magnification: 100×)

    Journal: Diagnostic Pathology

    Article Title: TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma

    doi: 10.1186/s13000-016-0457-7

    Figure Lengend Snippet: Representative of TRPV6 expression in three pairs of ESCC tumor and adjacent non-tumor tissue detected by immunostaining with anti-TRPV6 antibody ( brown ). (magnification: 100×)

    Article Snippet: The slides were then incubated with rabbit polyclonal antibody against TRPV6 (alomone labs) at a dilution of 1:50 at 4 °C overnight and subsequently incubated with biotinylated goat anti-rabbit immunoglobulin at a concentration of 1:100 for 30 min at 37 °C.

    Techniques: Expressing, Immunostaining

    Kaplan-Meier curves showed that no significant association between TRPV6 expression and disease-specific survival of esophageal squamous cell carcinoma was noted either in mRNA cohort ( a ) or protein cohort ( b )

    Journal: Diagnostic Pathology

    Article Title: TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma

    doi: 10.1186/s13000-016-0457-7

    Figure Lengend Snippet: Kaplan-Meier curves showed that no significant association between TRPV6 expression and disease-specific survival of esophageal squamous cell carcinoma was noted either in mRNA cohort ( a ) or protein cohort ( b )

    Article Snippet: The slides were then incubated with rabbit polyclonal antibody against TRPV6 (alomone labs) at a dilution of 1:50 at 4 °C overnight and subsequently incubated with biotinylated goat anti-rabbit immunoglobulin at a concentration of 1:100 for 30 min at 37 °C.

    Techniques: Expressing

    E2, BPA, and OP change the expressions of TRPV6 , TRPV5 , PMCA1 , and NCX1 in maternal uterus and implantation sites. Mice were sacrificed at GD 4.5 (24 h after final injection) to collect uterus tissues and at GD 5.5 (after 48 h after final injection) to collect implantation sites. The mRNA expressions of calcium transporter channel genes in uterus and implantation sites were assessed. The mRNA levels of TRPV6 , TRPV5 , PMCA1 , and NCX1 genes were measured by using real-time PCR and were normalized to that of 18S ribosomal RNA (RN18S). In uterus, ( a ) the expressions of TRPV5 mRNA were significantly high in the E2, E2 + ICI, BPA + ICI, OP, and OP + ICI groups; ( b ) TRPV6 mRNA level changes were similar to those for TRPV5 expression. mRNA expression of TRPV5 and TRPV6 in uteri were higher in BPA + ICI group than in the BPA group; ( c , d ) mRNA level of PMCA1 and NCX1 were significantly decreased by E2 and E2 + ICI. In implantation sites; ( e – h ) the mRNA levels of TRPV6 , TRPV5 , PMCA1 , and NCX1 , respectively, were markedly low in all groups. Statistical significance was determined by two-way ANOVA. * p

    Journal: International Journal of Environmental Research and Public Health

    Article Title: Effects of Bisphenol A and 4-tert-Octylphenol on Embryo Implantation Failure in Mouse

    doi: 10.3390/ijerph15081614

    Figure Lengend Snippet: E2, BPA, and OP change the expressions of TRPV6 , TRPV5 , PMCA1 , and NCX1 in maternal uterus and implantation sites. Mice were sacrificed at GD 4.5 (24 h after final injection) to collect uterus tissues and at GD 5.5 (after 48 h after final injection) to collect implantation sites. The mRNA expressions of calcium transporter channel genes in uterus and implantation sites were assessed. The mRNA levels of TRPV6 , TRPV5 , PMCA1 , and NCX1 genes were measured by using real-time PCR and were normalized to that of 18S ribosomal RNA (RN18S). In uterus, ( a ) the expressions of TRPV5 mRNA were significantly high in the E2, E2 + ICI, BPA + ICI, OP, and OP + ICI groups; ( b ) TRPV6 mRNA level changes were similar to those for TRPV5 expression. mRNA expression of TRPV5 and TRPV6 in uteri were higher in BPA + ICI group than in the BPA group; ( c , d ) mRNA level of PMCA1 and NCX1 were significantly decreased by E2 and E2 + ICI. In implantation sites; ( e – h ) the mRNA levels of TRPV6 , TRPV5 , PMCA1 , and NCX1 , respectively, were markedly low in all groups. Statistical significance was determined by two-way ANOVA. * p

    Article Snippet: The membrane was then blocked in TBS-T containing 5% skim milk for 60 min, then incubated overnight in primary antibodies for: TRPV5 (Santa Cruz Biotechnology, Dallas, TX, USA, dilute 1:3000), TRPV6 (Alomone labs, Jerusalem, Israel, catalog: ACC-036, diluted 1:3000), PMCA1 (Swant, Marly, Switzerland, dilute 1:3000), NCX1 (Abcam, Cambridge, UK, dilute 1:3000), MUC1 (Abcam, dilute 1:3000), or β-actin (Cell Signaling Technology, Danvers, MA, USA, diluted 1:3000).

    Techniques: Mouse Assay, Injection, Real-time Polymerase Chain Reaction, Expressing